Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Discovery Labs Plans Date With FDA On Surfaxin

This article was originally published in The Pink Sheet Daily

Executive Summary

$60 million financing deal will help bring first synthetic surfactant to market, firm says.

You may also be interested in...



Discovery Labs To Respond To Surfaxin “Approvable” Letter In September

Additional data must be collected on biological activity test, lipid-related impurities.

Discovery Labs To Respond To Surfaxin “Approvable” Letter In September

Additional data must be collected on biological activity test, lipid-related impurities.

Third Time’s Not A Charm: Discovery’s Surfaxin Receives “Approvable” Letter

Synthetic surfactant for prevention of respiratory distress syndrome in premature infants is deemed “approvable” by FDA.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel